| Abstract P180 – Table 1. Baseline characteristics. Data are median (IQR) or n (%) unless otherwise stated. | |
|---|---|
| Total (n = 296) | |
| Age (years); median (max, min) | 64 (60, 77) |
| Sex | |
| Female | 147 (49.7%) |
| Male | 149 (50.3%) |
| Race: Black | 296 (100%) |
| Any alcohol use in past 12 months | |
| No | 292 (98.7%) |
| Yes | 4 (1.4%) |
| Ever smoked | |
| No | 289 (97.6%) |
| Yes | 7 (2.4%) |
| Body mass index (kg/m2) | 27.5 (24.0, 30.9) |
| HBV co‐infection | 3 (1.0%) |
| HIV‐1 RNA <50 copies/mL | 296 (100%) |
| Median enrolment CD4 count (cells/uL) | 632 (483, 808) |
| Median nadir CD4 count (cells/uL) | 25 (18, 31) |
| CrCl <60 mL/min | 105 (35.6%) |
| Time since HIV diagnosis (years) | 12.6 (9.1, 15.4) |
| Time on ART (years) | 9.5 (5.3, 9.6) |
| Baseline ART regimen | |
| DTG + TDF + 3TC | 279 (94.3%) |
| DTG + ABC + 3TC | 15 (5.1%) |
| DTG + AZT + 3TC | 1 (0.3%) |
| EFV + TDF + 3TC | 1 (0.3%) |
| BMD lumbar spine (g/cm2) | 0.88 (0.78, 1.0) |
| BMD T‐score lumbar spine | ‐2.7 (‐3.5, ‐1.6) |
| BMD total hip (g/cm2) | 0.88 (0.80, 0.99) |
| BMD T‐score total hip | ‐1.3 (‐1.9, ‐0.7) |
| BMD category (using lowest T‐score from lumbar spine or total hip) | |
| Normal | 31 (10.5%) |
| Osteopenia | 86 (29.1%) |
| Osteoporosis | 179 (60.5%) |
| Treatment of osteoporosis recommended based on FRAX (without input of BMD)a | 10 (3.4%) |
3TC, lamivudine; ABC, abacavir; AZT, zidovudine; BMD, bone mineral density; CrCl, creatine clearance using the Cockcroft‐Gault equation; DTG, dolutegravir; EFV, efavirenz; FRAX, fracture risk assessment tool; TDF, tenofovir disoproxil fumarate.
aTreatment of osteoporosis is recommended if 10‐year probability of major osteoporotic fractures is ≥20% or of hip fracture is ≥3%.